

OFFICE OF THE SECRETARY OF STATE

TOBIAS READ

SECRETARY OF STATE

MICHAEL KAPLAN

DEPUTY SECRETARY OF STATE



ARCHIVES DIVISION

STEPHANIE CLARK

DIRECTOR

800 SUMMER STREET NE

SALEM, OR 97310

503-373-0701

PERMANENT ADMINISTRATIVE ORDER

BP 2-2026
CHAPTER 855
BOARD OF PHARMACY

FILED

01/23/2026 8:39 AM
ARCHIVES DIVISION
SECRETARY OF STATE
& LEGISLATIVE COUNSEL

FILING CAPTION: Protocols, Standard Vaccination Protocols and Formulary: Devices & Supplies

EFFECTIVE DATE: 01/23/2026

AGENCY APPROVED DATE: 01/22/2026

CONTACT: Rachel Melvin
971-673-0001
pharmacy.rulemaking@bop.oregon.gov

800 NE Oregon St., Suite 150
Portland, OR 97232

Filed By:
Rachel Melvin
Rules Coordinator

RULES:

855-115-0340, 855-115-0345

AMEND: 855-115-0340

RULE TITLE: Services: Prescribing - Formulary

NOTICE FILED DATE: 12/17/2025

RULE SUMMARY: Amends current rule by adding Epinephrine to the Drug and Devices Formulary.

RULE TEXT:

A Pharmacist may prescribe, according to OAR 855-115-0330 and OAR 855-115-0335, an FDA-approved drug and device listed in the Formulary, pursuant to a diagnosis by a health care practitioner who has prescriptive authority and who is qualified to make the diagnosis. Formulary devices and supplies:

- (1) Diabetic blood sugar testing supplies;
- (2) Injection supplies;
- (3) Nebulizers and associated supplies;
- (4) Inhalation spacers;
- (5) Peak flow meters;
- (6) International Normalized Ratio (INR) testing supplies;
- (7) Enteral nutrition supplies;
- (8) Ostomy products and supplies; and
- (9) Non-invasive blood pressure monitors; and
- (10) Continuous glucose monitors and associated supplies; and
- (11) Epinephrine.

STATUTORY/OTHER AUTHORITY: ORS 689.205

STATUTES/OTHER IMPLEMENTED: ORS 689.645, ORS 689.649

AMEND: 855-115-0345

REPEAL: Temporary 855-115-0345 from BP 13-2025

RULE TITLE: Services: Prescribing Pursuant to - Protocol

NOTICE FILED DATE: 12/17/2025

RULE SUMMARY: Amends current rule by adding new versions for HIV Post-Exposure Prophylaxis (PEP) protocol, HIV Pre-Exposure Prophylaxis (PrEP) protocol, amends Coronavirus 19 vaccination protocol, amends Influenza vaccine protocol, adopts Respiratory Syncytial Virus protocol v. 09/2025, amends current versions of the Vaccination Protocol for Adults 18 Years of Age and Older & Assessment and Treatment Care Pathway and Vaccination Protocol for Persons 7 through 17 Years of Age and Treatment Care Pathway by adding Chikungunya v. 5/13/2025. Adopts Managing Adverse Reactions protocol v. 08/2025. Repeals Vaccination Protocol for Ages 3 through 6 Years (v. 08/13/2025) and Vaccination Protocol for Ages 6 months through 2 Years v. 08/13/2025.

RULE TEXT:

A Pharmacist may prescribe, according to OAR 855-115-0330 and OAR 855-115-0335, FDA-approved drugs and devices pursuant to a Protocol. Protocols in their entirety are adopted by the board by this rule pursuant to the respective effective date referenced and can be found on the board website at <https://www.oregon.gov/pharmacy/Pages/PFAC.aspx>.

(1) Continuation of therapy Protocol including emergency refills of insulin and early refills of opioid use disorder medications (v. 08/2024).

(2) Conditions Protocols:

(a) Cough and cold symptom management:

(A) Benzonatate (v. 06/2021);

(B) Short-acting beta agonists (v. 06/2021);

(C) Intranasal corticosteroids (v. 06/2021);

(b) COVID-19 Antigen Self-Test (v. 12/2021);

(c) SARS-CoV-2 Antiviral (v. 08/2024).

(3) Preventative Care Protocols:

(a) Emergency Contraception (v. 06/2021);

(b) Male and female condoms (v. 06/2021);

(c) Tobacco Cessation, NRT (Nicotine Replacement Therapy) and Non-NRT (v. 06/2024);

(d) Travel Medications (v. 06/2024);

(e) HIV Post-exposure Prophylaxis (PEP) (v. 01/2026);

(f) HIV Pre-exposure Prophylaxis (PrEP) (v. 01/2026);

(g) Contraception (v. 06/2025);

(h) Sexually Transmitted Infections Post-exposure Prophylaxis (STI PEP) (v. 06/2024);

(i) Short-acting Opioid Antagonists (v. 06/2024); and

(4) Vaccine Protocols:

(a) Vaccination Protocol for Adults 18 Years of Age and Older (v. 01/2026);

(b) Vaccination Protocol for Ages 7 through 17 Years (v. 01/2026); and

(c) Vaccination Protocol for Managing Adverse Reactions (v. 08/2025).

(5) Board Excluded Vaccine Protocols:

(a) Coronavirus 19 (v. 01/2026);

(b) Influenza (v. 01/2026); and

(c) Respiratory Syncytial Virus (v. 09/2025).

[Publications: Publications referenced are available from the agency.]

STATUTORY/OTHER AUTHORITY: ORS 689.205, ORS 689.005

STATUTES/OTHER IMPLEMENTED: ORS 689.645, ORS 689.649, ORS 689.689, ORS 689.005

OFFICE OF THE SECRETARY OF STATE

TOBIAS READ

SECRETARY OF STATE

MICHAEL KAPLAN

DEPUTY SECRETARY OF STATE



ARCHIVES DIVISION

STEPHANIE CLARK

DIRECTOR

800 SUMMER STREET NE

SALEM, OR 97310

503-373-0701

PERMANENT ADMINISTRATIVE ORDER

BP 2-2026

CHAPTER 855

BOARD OF PHARMACY

FILED

01/23/2026 8:39 AM

ARCHIVES DIVISION
SECRETARY OF STATE
& LEGISLATIVE COUNSEL

FILING CAPTION: Protocols, Standard Vaccination Protocols and Formulary: Devices & Supplies

EFFECTIVE DATE: 01/23/2026

AGENCY APPROVED DATE: 01/22/2026

CONTACT: Rachel Melvin

971-673-0001

pharmacy.rulemaking@bop.oregon.gov

800 NE Oregon St., Suite 150

Portland, OR 97232

Filed By:

Rachel Melvin

Rules Coordinator

RULES:

855-115-0340, 855-115-0345

AMEND: 855-115-0340

NOTICE FILED DATE: 12/17/2025

RULE SUMMARY: Amends current rule by adding Epinephrine to the Drug and Devices Formulary.

CHANGES TO RULE:

855-115-0340

Services: Prescribing - Formulary

A Pharmacist may prescribe, according to OAR 855-115-0330 and OAR 855-115-0335, an FDA-approved drug and device listed in the Formulary, pursuant to a diagnosis by a health care practitioner who has prescriptive authority and who is qualified to make the diagnosis. Formulary devices and supplies:~~¶~~

- (1) Diabetic blood sugar testing supplies;~~¶~~
- (2) Injection supplies;~~¶~~
- (3) Nebulizers and associated supplies;~~¶~~
- (4) Inhalation spacers;~~¶~~
- (5) Peak flow meters;~~¶~~
- (6) International Normalized Ratio (INR) testing supplies;~~¶~~
- (7) Enteral nutrition supplies;~~¶~~
- (8) Ostomy products and supplies; and~~¶~~
- (9) Non-invasive blood pressure monitors; and~~¶~~
- (10) Continuous glucose monitors and associated supplies; and~~¶~~
- (11) Epinephrine.

Statutory/Other Authority: ORS 689.205

Statutes/Other Implemented: ORS 689.645, ORS 689.649

AMEND: 855-115-0345

REPEAL: Temporary 855-115-0345 from BP 13-2025

NOTICE FILED DATE: 12/17/2025

RULE SUMMARY: Amends current rule by adding new versions for HIV Post-Exposure Prophylaxis (PEP) protocol, HIV Pre-Exposure Prophylaxis (PrEP) protocol, amends Coronavirus 19 vaccination protocol, amends Influenza vaccine protocol, adopts Respiratory Syncytial Virus protocol v. 09/2025, amends current versions of the Vaccination Protocol for Adults 18 Years of Age and Older & Assessment and Treatment Care Pathway and Vaccination Protocol for Persons 7 through 17 Years of Age and Treatment Care Pathway by adding Chikungunya v. 5/13/2025. Adopts Managing Adverse Reactions protocol v. 08/2025. Repeals Vaccination Protocol for Ages 3 through 6 Years (v. 08/13/2025) and Vaccination Protocol for Ages 6 months through 2 Years v. 08/13/2025.

CHANGES TO RULE:

855-115-0345

Services: Prescribing Pursuant to - Protocol

A Pharmacist may prescribe, according to OAR 855-115-0330 and OAR 855-115-0335, FDA-approved drugs and devices pursuant to a Protocol. Protocols in their entirety are adopted by the board by this rule pursuant to the respective effective date referenced and can be found on the board website at

<https://www.oregon.gov/pharmacy/Pages/PFAC.aspx>.¶

(1) Continuation of therapy Protocol including emergency refills of insulin and early refills of opioid use disorder medications (v. 08/2024).¶

(2) Conditions Protocols:¶

(a) Cough and cold symptom management:¶

(A) Benzonatate (v. 06/2021);¶

(B) Short-acting beta agonists (v. 06/2021);¶

(C) Intranasal corticosteroids (v. 06/2021);¶

(b) COVID-19 Antigen Self-Test (v. 12/2021);¶

(c) SARS-CoV-2 Antiviral (v. 08/2024).¶

(3) Preventative Care Protocols:¶

(a) Emergency Contraception (v. 06/2021);¶

(b) Male and female condoms (v. 06/2021);¶

(c) Tobacco Cessation, NRT (Nicotine Replacement Therapy) and Non-NRT (v. 06/2024);¶

(d) Travel Medications (v. 06/2024);¶

(e) HIV Post-exposure Prophylaxis (PEP) (v. 06/20236);¶

(f) HIV Pre-exposure Prophylaxis (PrEP) (v. 06/20236);¶

(g) Contraception (v. 06/2025);¶

(h) Sexually Transmitted Infections Post-exposure Prophylaxis (STI PEP) (v. 06/2024);¶

(i) Short-acting Opioid Antagonists (v. 06/2024); and¶

(4) Vaccine Protocols:¶

(a) Vaccination Protocol for Adults 18 Years of Age and Older (v. 08/20256);¶

(b) Vaccination Protocol for Ages 7 through 17 Years (v. 08/20256); and¶

(c) Vaccination Protocol for Ages 3 through 6 Year Managing Adverse Reactions (v. 08/2025);¶

(d).¶

(5) Board Excluded Vaccination Protocol for Ages 6 months through 2 Years:¶

(a) Coronavirus 19 (v. 01/2026);¶

(b) Influenza (v. 08/20256); and¶

(c) Vaccination Protocol for Managing Adverse Reaction Respiratory Syncytial Virus (v. 08/2025).¶

[Publications: Publications referenced are available from the agency.]

Statutory/Other Authority: ORS 689.205, ORS 689.005

Statutes/Other Implemented: ORS 689.645, ORS 689.649, ORS 689.689, ORS 689.005